0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Monoclonal Antibody for Gastric Cancer Market Research Report 2026
Published Date: 2026-01-21
|
Report Code: QYRE-Auto-22X18588
Home | Market Reports | Health| Health Conditions| Cancer
Global Monoclonal Antibody for Gastric Cancer Market Research Report 2024
BUY CHAPTERS

Global Monoclonal Antibody for Gastric Cancer Market Research Report 2026

Code: QYRE-Auto-22X18588
Report
2026-01-21
Pages:111
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Monoclonal Antibody for Gastric Cancer Market Size

The global Monoclonal Antibody for Gastric Cancer market was valued at US$ 1564 million in 2025 and is anticipated to reach US$ 3422 million by 2032, at a CAGR of 12.0% from 2026 to 2032.

Monoclonal Antibody for Gastric Cancer Market

Monoclonal Antibody for Gastric Cancer Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Monoclonal Antibody for Gastric Cancer competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Monoclonal Antibodies for Gastric Cancer are a class of lab-made proteins targeting specific antigens on the surface of gastric cancer cells. They can recognize and bind these antigens with high specificity, so as to activate the immune system to attack gastric cancer cells or directly inhibit the growth and spread of cancer cells. They are an important part of targeted therapies for the treatment of gastric cancer.
The North American market for Monoclonal Antibody for Gastric Cancer is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Monoclonal Antibody for Gastric Cancer is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Monoclonal Antibody for Gastric Cancer include Genentech, Eli Lilly & Co, Bristol Myers Squibb Co, Merck & Co., Inc, BeiGene Ltd, Astellas Pharma, Inc., Innovent Biologics, Inc, CStone Pharmaceuticals, Henlius, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Monoclonal Antibody for Gastric Cancer market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Monoclonal Antibody for Gastric Cancer. The Monoclonal Antibody for Gastric Cancer market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Monoclonal Antibody for Gastric Cancer market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Monoclonal Antibody for Gastric Cancer manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Monoclonal Antibody for Gastric Cancer Market Report

Report Metric Details
Report Name Monoclonal Antibody for Gastric Cancer Market
Accounted market size in 2025 US$ 1564 million
Forecasted market size in 2032 US$ 3422 million
CAGR 12.0%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • 4 mg/mL
  • 5 mg/mL
  • 10 mg/mL
by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Genentech, Eli Lilly & Co, Bristol Myers Squibb Co, Merck & Co., Inc, BeiGene Ltd, Astellas Pharma, Inc., Innovent Biologics, Inc, CStone Pharmaceuticals, Henlius
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Monoclonal Antibody for Gastric Cancer manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Monoclonal Antibody for Gastric Cancer sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Monoclonal Antibody for Gastric Cancer Market growing?

Ans: The Monoclonal Antibody for Gastric Cancer Market witnessing a CAGR of 12.0% during the forecast period 2026-2032.

What is the Monoclonal Antibody for Gastric Cancer Market size in 2032?

Ans: The Monoclonal Antibody for Gastric Cancer Market size in 2032 will be US$ 3422 million.

Who are the main players in the Monoclonal Antibody for Gastric Cancer Market report?

Ans: The main players in the Monoclonal Antibody for Gastric Cancer Market are Genentech, Eli Lilly & Co, Bristol Myers Squibb Co, Merck & Co., Inc, BeiGene Ltd, Astellas Pharma, Inc., Innovent Biologics, Inc, CStone Pharmaceuticals, Henlius

What are the Application segmentation covered in the Monoclonal Antibody for Gastric Cancer Market report?

Ans: The Applications covered in the Monoclonal Antibody for Gastric Cancer Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Monoclonal Antibody for Gastric Cancer Market report?

Ans: The Types covered in the Monoclonal Antibody for Gastric Cancer Market report are 4 mg/mL, 5 mg/mL, 10 mg/mL

1 Monoclonal Antibody for Gastric Cancer Market Overview
1.1 Product Definition
1.2 Monoclonal Antibody for Gastric Cancer by Type
1.2.1 Global Monoclonal Antibody for Gastric Cancer Market Value by Type: 2025 vs 2032
1.2.2 4 mg/mL
1.2.3 5 mg/mL
1.2.4 10 mg/mL
1.3 Monoclonal Antibody for Gastric Cancer by Application
1.3.1 Global Monoclonal Antibody for Gastric Cancer Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Monoclonal Antibody for Gastric Cancer Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibody for Gastric Cancer Revenue 2021–2032
1.4.2 Global Monoclonal Antibody for Gastric Cancer Sales 2021–2032
1.4.3 Global Monoclonal Antibody for Gastric Cancer Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Monoclonal Antibody for Gastric Cancer Market Competition by Manufacturers
2.1 Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Manufacturers (2021–2026)
2.2 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Monoclonal Antibody for Gastric Cancer Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Monoclonal Antibody for Gastric Cancer, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Product Types and Applications
2.7 Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Date of Entry into the Industry
2.8 Global Monoclonal Antibody for Gastric Cancer Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibody for Gastric Cancer Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Monoclonal Antibody for Gastric Cancer Players Market Share by Revenue
2.8.3 Global Monoclonal Antibody for Gastric Cancer Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibody for Gastric Cancer Market Scenario by Region
3.1 Global Monoclonal Antibody for Gastric Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2021–2032
3.2.1 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2021–2026
3.2.2 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2027–2032
3.3 Global Monoclonal Antibody for Gastric Cancer Revenue by Region: 2021–2032
3.3.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Region: 2021–2026
3.3.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Region: 2027–2032
3.4 North America Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibody for Gastric Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Monoclonal Antibody for Gastric Cancer Sales by Country (2021–2032)
3.4.3 North America Monoclonal Antibody for Gastric Cancer Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibody for Gastric Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Monoclonal Antibody for Gastric Cancer Sales by Country (2021–2032)
3.5.3 Europe Monoclonal Antibody for Gastric Cancer Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibody for Gastric Cancer Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Region (2021–2032)
3.6.3 Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibody for Gastric Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Monoclonal Antibody for Gastric Cancer Sales by Country (2021–2032)
3.7.3 Latin America Monoclonal Antibody for Gastric Cancer Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibody for Gastric Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibody for Gastric Cancer Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (2021–2032)
3.8.3 Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibody for Gastric Cancer Sales by Type (2021–2032)
4.1.1 Global Monoclonal Antibody for Gastric Cancer Sales by Type (2021–2026)
4.1.2 Global Monoclonal Antibody for Gastric Cancer Sales by Type (2027–2032)
4.1.3 Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2021–2032)
4.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2021–2032)
4.2.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2021–2026)
4.2.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2027–2032)
4.2.3 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2021–2032)
4.3 Global Monoclonal Antibody for Gastric Cancer Price by Type (2021–2032)
5 Segment by Application
5.1 Global Monoclonal Antibody for Gastric Cancer Sales by Application (2021–2032)
5.1.1 Global Monoclonal Antibody for Gastric Cancer Sales by Application (2021–2026)
5.1.2 Global Monoclonal Antibody for Gastric Cancer Sales by Application (2027–2032)
5.1.3 Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2021–2032)
5.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2021–2032)
5.2.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2021–2026)
5.2.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2027–2032)
5.2.3 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2021–2032)
5.3 Global Monoclonal Antibody for Gastric Cancer Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Genentech
6.1.1 Genentech Company Information
6.1.2 Genentech Description and Business Overview
6.1.3 Genentech Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Genentech Monoclonal Antibody for Gastric Cancer Product Portfolio
6.1.5 Genentech Recent Developments/Updates
6.2 Eli Lilly & Co
6.2.1 Eli Lilly & Co Company Information
6.2.2 Eli Lilly & Co Description and Business Overview
6.2.3 Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Product Portfolio
6.2.5 Eli Lilly & Co Recent Developments/Updates
6.3 Bristol Myers Squibb Co
6.3.1 Bristol Myers Squibb Co Company Information
6.3.2 Bristol Myers Squibb Co Description and Business Overview
6.3.3 Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Product Portfolio
6.3.5 Bristol Myers Squibb Co Recent Developments/Updates
6.4 Merck & Co., Inc
6.4.1 Merck & Co., Inc Company Information
6.4.2 Merck & Co., Inc Description and Business Overview
6.4.3 Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Product Portfolio
6.4.5 Merck & Co., Inc Recent Developments/Updates
6.5 BeiGene Ltd
6.5.1 BeiGene Ltd Company Information
6.5.2 BeiGene Ltd Description and Business Overview
6.5.3 BeiGene Ltd Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 BeiGene Ltd Monoclonal Antibody for Gastric Cancer Product Portfolio
6.5.5 BeiGene Ltd Recent Developments/Updates
6.6 Astellas Pharma, Inc.
6.6.1 Astellas Pharma, Inc. Company Information
6.6.2 Astellas Pharma, Inc. Description and Business Overview
6.6.3 Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Product Portfolio
6.6.5 Astellas Pharma, Inc. Recent Developments/Updates
6.7 Innovent Biologics, Inc
6.7.1 Innovent Biologics, Inc Company Information
6.7.2 Innovent Biologics, Inc Description and Business Overview
6.7.3 Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Product Portfolio
6.7.5 Innovent Biologics, Inc Recent Developments/Updates
6.8 CStone Pharmaceuticals
6.8.1 CStone Pharmaceuticals Company Information
6.8.2 CStone Pharmaceuticals Description and Business Overview
6.8.3 CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Product Portfolio
6.8.5 CStone Pharmaceuticals Recent Developments/Updates
6.9 Henlius
6.9.1 Henlius Company Information
6.9.2 Henlius Description and Business Overview
6.9.3 Henlius Monoclonal Antibody for Gastric Cancer Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Henlius Monoclonal Antibody for Gastric Cancer Product Portfolio
6.9.5 Henlius Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibody for Gastric Cancer Industry Chain Analysis
7.2 Monoclonal Antibody for Gastric Cancer Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibody for Gastric Cancer Production Mode & Process Analysis
7.4 Monoclonal Antibody for Gastric Cancer Sales and Marketing
7.4.1 Monoclonal Antibody for Gastric Cancer Sales Channels
7.4.2 Monoclonal Antibody for Gastric Cancer Distributors
7.5 Monoclonal Antibody for Gastric Cancer Customer Analysis
8 Monoclonal Antibody for Gastric Cancer Market Dynamics
8.1 Monoclonal Antibody for Gastric Cancer Industry Trends
8.2 Monoclonal Antibody for Gastric Cancer Market Drivers
8.3 Monoclonal Antibody for Gastric Cancer Market Challenges
8.4 Monoclonal Antibody for Gastric Cancer Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Monoclonal Antibody for Gastric Cancer Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Monoclonal Antibody for Gastric Cancer Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Monoclonal Antibody for Gastric Cancer Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Monoclonal Antibody for Gastric Cancer Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Monoclonal Antibody for Gastric Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Monoclonal Antibody for Gastric Cancer, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Product Types and Applications
 Table 12. Global Key Manufacturers of Monoclonal Antibody for Gastric Cancer, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Monoclonal Antibody for Gastric Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on Monoclonal Antibody for Gastric Cancer Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Monoclonal Antibody for Gastric Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Monoclonal Antibody for Gastric Cancer Sales by Region (K Units), 2021–2026
 Table 18. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2021–2026)
 Table 19. Global Monoclonal Antibody for Gastric Cancer Sales by Region (K Units), 2027–2032
 Table 20. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2027–2032)
 Table 21. Global Monoclonal Antibody for Gastric Cancer Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2021–2026)
 Table 23. Global Monoclonal Antibody for Gastric Cancer Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2027–2032)
 Table 25. North America Monoclonal Antibody for Gastric Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Monoclonal Antibody for Gastric Cancer Sales by Country (K Units), 2021–2026
 Table 27. North America Monoclonal Antibody for Gastric Cancer Sales by Country (K Units), 2027–2032
 Table 28. North America Monoclonal Antibody for Gastric Cancer Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Monoclonal Antibody for Gastric Cancer Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Monoclonal Antibody for Gastric Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Monoclonal Antibody for Gastric Cancer Sales by Country (K Units), 2021–2026
 Table 32. Europe Monoclonal Antibody for Gastric Cancer Sales by Country (K Units), 2027–2032
 Table 33. Europe Monoclonal Antibody for Gastric Cancer Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Monoclonal Antibody for Gastric Cancer Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Monoclonal Antibody for Gastric Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Monoclonal Antibody for Gastric Cancer Sales by Country (K Units), 2021–2026
 Table 42. Latin America Monoclonal Antibody for Gastric Cancer Sales by Country (K Units), 2027–2032
 Table 43. Latin America Monoclonal Antibody for Gastric Cancer Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Monoclonal Antibody for Gastric Cancer Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) by Type (2021–2026)
 Table 51. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) by Type (2027–2032)
 Table 52. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2021–2026)
 Table 53. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2027–2032)
 Table 54. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2021–2026)
 Table 57. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2027–2032)
 Table 58. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) by Application (2021–2026)
 Table 61. Global Monoclonal Antibody for Gastric Cancer Sales (K Units) by Application (2027–2032)
 Table 62. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2021–2026)
 Table 63. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2027–2032)
 Table 64. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Monoclonal Antibody for Gastric Cancer Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2021–2026)
 Table 67. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2027–2032)
 Table 68. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Application (2027–2032)
 Table 70. Genentech Company Information
 Table 71. Genentech Description and Business Overview
 Table 72. Genentech Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Genentech Monoclonal Antibody for Gastric Cancer Product
 Table 74. Genentech Recent Developments/Updates
 Table 75. Eli Lilly & Co Company Information
 Table 76. Eli Lilly & Co Description and Business Overview
 Table 77. Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Product
 Table 79. Eli Lilly & Co Recent Developments/Updates
 Table 80. Bristol Myers Squibb Co Company Information
 Table 81. Bristol Myers Squibb Co Description and Business Overview
 Table 82. Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Product
 Table 84. Bristol Myers Squibb Co Recent Developments/Updates
 Table 85. Merck & Co., Inc Company Information
 Table 86. Merck & Co., Inc Description and Business Overview
 Table 87. Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Product
 Table 89. Merck & Co., Inc Recent Developments/Updates
 Table 90. BeiGene Ltd Company Information
 Table 91. BeiGene Ltd Description and Business Overview
 Table 92. BeiGene Ltd Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. BeiGene Ltd Monoclonal Antibody for Gastric Cancer Product
 Table 94. BeiGene Ltd Recent Developments/Updates
 Table 95. Astellas Pharma, Inc. Company Information
 Table 96. Astellas Pharma, Inc. Description and Business Overview
 Table 97. Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Product
 Table 99. Astellas Pharma, Inc. Recent Developments/Updates
 Table 100. Innovent Biologics, Inc Company Information
 Table 101. Innovent Biologics, Inc Description and Business Overview
 Table 102. Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Product
 Table 104. Innovent Biologics, Inc Recent Developments/Updates
 Table 105. CStone Pharmaceuticals Company Information
 Table 106. CStone Pharmaceuticals Description and Business Overview
 Table 107. CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Product
 Table 109. CStone Pharmaceuticals Recent Developments/Updates
 Table 110. Henlius Company Information
 Table 111. Henlius Description and Business Overview
 Table 112. Henlius Monoclonal Antibody for Gastric Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Henlius Monoclonal Antibody for Gastric Cancer Product
 Table 114. Henlius Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. Monoclonal Antibody for Gastric Cancer Distributors List
 Table 118. Monoclonal Antibody for Gastric Cancer Customers List
 Table 119. Monoclonal Antibody for Gastric Cancer Market Trends
 Table 120. Monoclonal Antibody for Gastric Cancer Market Drivers
 Table 121. Monoclonal Antibody for Gastric Cancer Market Challenges
 Table 122. Monoclonal Antibody for Gastric Cancer Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Monoclonal Antibody for Gastric Cancer
 Figure 2. Global Monoclonal Antibody for Gastric Cancer Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Monoclonal Antibody for Gastric Cancer Market Share by Type: 2025 & 2032
 Figure 4. 4 mg/mL Product Picture
 Figure 5. 5 mg/mL Product Picture
 Figure 6. 10 mg/mL Product Picture
 Figure 7. Global Monoclonal Antibody for Gastric Cancer Market Value by Application (US$ Million), 2021–2032
 Figure 8. Global Monoclonal Antibody for Gastric Cancer Market Share by Application: 2025 & 2032
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. Others
 Figure 12. Global Monoclonal Antibody for Gastric Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global Monoclonal Antibody for Gastric Cancer Market Size (US$ Million), 2021–2032
 Figure 14. Global Monoclonal Antibody for Gastric Cancer Sales (K Units), 2021–2032
 Figure 15. Global Monoclonal Antibody for Gastric Cancer Average Price (US$/Unit), 2021–2032
 Figure 16. Monoclonal Antibody for Gastric Cancer Report Years Considered
 Figure 17. Monoclonal Antibody for Gastric Cancer Sales Share by Manufacturers in 2025
 Figure 18. Global Monoclonal Antibody for Gastric Cancer Revenue Share by Manufacturers in 2025
 Figure 19. Top 5 and Top 10 Global Monoclonal Antibody for Gastric Cancer Players: Market Share by Revenue in Monoclonal Antibody for Gastric Cancer in 2025
 Figure 20. Monoclonal Antibody for Gastric Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 21. Global Monoclonal Antibody for Gastric Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 22. North America Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021–2032)
 Figure 23. North America Monoclonal Antibody for Gastric Cancer Revenue Market Share by Country (2021–2032)
 Figure 24. United States Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Canada Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 26. Europe Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021–2032)
 Figure 27. Europe Monoclonal Antibody for Gastric Cancer Revenue Market Share by Country (2021–2032)
 Figure 28. Germany Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. France Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. U.K. Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Italy Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Russia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2021–2032)
 Figure 34. Asia Pacific Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2021–2032)
 Figure 35. China Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Japan Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. South Korea Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. India Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Australia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. China Taiwan Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Southeast Asia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Latin America Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021–2032)
 Figure 43. Latin America Monoclonal Antibody for Gastric Cancer Revenue Market Share by Country (2021–2032)
 Figure 44. Mexico Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Brazil Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Argentina Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Colombia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021–2032)
 Figure 49. Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue Market Share by Country (2021–2032)
 Figure 50. Turkey Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Saudi Arabia Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. UAE Monoclonal Antibody for Gastric Cancer Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Global Sales Market Share of Monoclonal Antibody for Gastric Cancer by Type (2021–2032)
 Figure 54. Global Revenue Market Share of Monoclonal Antibody for Gastric Cancer by Type (2021–2032)
 Figure 55. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Type (2021–2032)
 Figure 56. Global Sales Market Share of Monoclonal Antibody for Gastric Cancer by Application (2021–2032)
 Figure 57. Global Revenue Market Share of Monoclonal Antibody for Gastric Cancer by Application (2021–2032)
 Figure 58. Global Monoclonal Antibody for Gastric Cancer Price (US$/Unit) by Application (2021–2032)
 Figure 59. Monoclonal Antibody for Gastric Cancer Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS